CA-TALKDESK
9.5.2024 07:01:35 CEST | Business Wire | Press release
Talkdesk®, Inc., a global AI-powered contact center leader for enterprises of all sizes, today announced that Simon Horrocks has joined Talkdesk as the Asia-Pacific (APAC) leader to help drive the company’s ongoing growth and expansion as an artificial intelligence (AI) leader in customer experience (CX).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508118657/en/
Simon Horrocks, Vice President of APAC at Talkdesk (Photo: Business Wire)
Horrocks joins Talkdesk with over 30 years of sales experience managing teams for startups and large organizations in APAC. Based in Sydney, Australia, he is focused on go-to-market acceleration and business expansion for Talkdesk in Australia and New Zealand (ANZ) and Southeast Asia. Horrocks’ appointment further highlights the company’s commitment to being an AI-first CX leader in APAC, as Talkdesk finalizes plans for a regional cloud in Australia and additional regional expansion.
Horrocks joined Talkdesk from Harness.io, where he led the charge in the APAC market as the U.S.-based software delivery platform start-up looked to make its mark in the region. Previously, he worked with several leading and prominent technology companies in APAC, including, AppDynamics, Cisco, IBM, and ScienceLogic.
In addition to Horrocks’ hire, Talkdesk recently promoted Miles Ennis to global sales leader and announced Munil Shah as the company’s chief technology officer (CTO). The appointments follow recent news of Talkdesk launching several groundbreaking and industry-first generative artificial intelligence (GenAI) innovations in CX, including Talkdesk Ascend Connect, Talkdesk Autopilot for Banking, Talkdesk Autopilot for Retail, and Talkdesk Autopilot for Healthcare. Under these new leaders, Talkdesk will capitalize on an extensive global opportunity as companies look to the power of GenAI to help them innovate and expand their businesses, improve customer experiences, and streamline operations.
Talkdesk operates at the forefront of the CX industry, helping companies globally to benefit from a new era of automation and intelligence with contact center solutions powered by Talkdesk AI.
The company was named a Leader in the G2 Spring 2024 Grid® Report for Contact Center category with over 1,800 five-star reviews and ranked #1 in multiple categories, including Enterprise Results and Usability Index for Contact Center Workforce, based on customers’ authentic feedback. Most recently, TrustRadius recognized Talkdesk with 2024 Top Rated Awards for contact center, call center workforce optimization, call recording, and voice over Internet Protocol (VoIP).
Supporting Quotes
William Welch, president and chief operating officer of Talkdesk, said, “APAC is an important market for Talkdesk. With Simon in this critical leadership position in our sales organization, we can drive further growth and success in the region. GenAI offers unparalleled opportunities for companies to elevate customer experience, and Talkdesk will be able to help more organizations globally to reap the benefits.”
Simon Horrocks, vice president of APAC at Talkdesk, commented: “Talkdesk is at the forefront of GenAI innovations in the contact center at a time when businesses need to deliver seamless CX more than ever. Talkdesk is already used by some of the largest banks, e-tailers, and BPOs in APAC, and I’m honored to join the company at such an exciting time, to continue the company’s global expansion momentum.”
About Talkdesk
Talkdesk® is a global cloud contact center leader for enterprises of all sizes. Talkdesk CX Cloud and Industry Experience Clouds help enterprises deliver modern customer service their way. Our trusted, flexible, and innovative contact center platform leverages AI and automation to drive exceptional outcomes for their customers and improve the bottom line. Serving enterprise customers in over 100 countries, we partner with our customers to deliver continuous innovation and breakthrough results. Our unwavering commitment to doing what we say we will do and our investment in the highest levels of security and reliability for our products make us second to none in the industry. Improve customer experiences, increase efficiency, and grow revenue with Talkdesk, a cloud contact center platform built for your industry. Learn more and take a self-guided demo at www.talkdesk.com.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508118657/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release
Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom